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Chronic kidney disease (CKD) is a worldwide public
health threat that increases risk of death due to
cardiovascular complications, including left ventric-
ular hypertrophy (LVH). Novel therapeutic targets
are needed to design treatments to alleviate the car-
diovascular burden of CKD. Previously, we demon-
strated that circulating concentrations of fibroblast
growth factor (FGF) 23 rise progressively in CKD
and induce LVH through an unknown FGF recep-
tor (FGFR)-dependent mechanism. Here, we report
that FGF23 exclusively activates FGFR4 on cardiac
myocytes to stimulate phospholipase Cg/calci-
neurin/nuclear factor of activated T cell signaling. A
specific FGFR4-blocking antibody inhibits FGF23-
induced hypertrophy of isolated cardiac myocytes
and attenuates LVH in rats with CKD. Mice lacking
FGFR4 do not develop LVH in response to elevated
FGF23, whereas knockin mice carrying an FGFR4
gain-of-function mutation spontaneously develop
LVH. Thus, FGF23 promotes LVH by activating
FGFR4, thereby establishing FGFR4 as a pharmaco-
logical target for reducing cardiovascular risk in CKD.
INTRODUCTION
Chronic kidney disease (CKD) is a global public health problem
that shortens lifespan, primarily by increasing risk of cardiovas-1020 Cell Metabolism 22, 1020–1032, December 1, 2015 ª2015 Elsecular disease (Eckardt et al., 2013). Novel therapeutic targets
are urgently needed to reduce the burden of cardiovascular dis-
ease in CKD.
Left ventricular hypertrophy (LVH) is a common pattern of
cardiovascular injury in CKD that affects up to 75% of individuals
by the time they reach end-stage renal disease (Faul et al., 2011).
By promoting heart failure and atrial and ventricular arrhythmias,
LVH is a powerful risk factor for cardiovascular events and death
(de Simone et al., 2008). The complex pathogenesis of LVH
involves ventricular pressure and volume overload, but emerging
data also implicate a novel role for the bone-derived, phosphate-
regulating hormone fibroblast growth factor (FGF) 23 (Gutie´rrez
et al., 2009).
The primary physiological effects of FGF23 to stimulate urinary
phosphate excretion and reduce circulating calcitriol concentra-
tions are mediated by FGF23 binding to FGF receptors (FGFR)
in the kidney, with a-klotho serving as the co-receptor that en-
hances binding affinity (Urakawa et al., 2006). Serum levels of
FGF23 rise progressively as kidney function declines, presum-
ably as a compensation to maintain neutral phosphate balance
in the setting of reduced glomerular filtration of phosphate
(Wolf, 2012). However, chronically elevated FGF23 levels may
be ultimately maladaptive in patients with CKD, given the power-
ful dose-dependent associations of higher FGF23with increased
risks of LVH, congestive heart failure, and death (Gutie´rrez et al.,
2008, 2009; Isakova et al., 2011).
FGF23 induces hypertrophic growth of cardiac myocytes
in vitro and LVH in rodents through a direct FGFR-dependent
mechanism, but independently of a-klotho, which is not ex-
pressed in cardiac myocytes (Faul et al., 2011). Whereas a-klo-
tho-expressing cells in the kidney respond toFGF23byactivating
the Ras/mitogen-activated protein kinase (MAPK) cascadevier Inc.
Figure 1. FGF23 Activates FGFR4 and PLCg Signaling in HEK293
Cells
(A) FGF23 treatment increases levels of phosphorylated PLCg in HEK293
cells within 30 min, as revealed by immunoprecipitation of endogenous PLCg
and western blot analysis of eluates with anti-phospho-PLCg. FGF23 does not
increase phosphorylation of FRS2a or ERK1/2, as shown by western blot
analyses of total protein extracts. In contrast, FGF23 induces phosphorylation
of FRS2a and ERK1/2, but not PLCg, in cells that overexpress FLAG-tagged
a-klotho (aKL). HEK293 cells that overexpress b-klotho (bKL) respond to
FGF23 similar to untransfected cells. FGF2 induces phosphorylation of FRS2a
and ERK1/2, regardless of presence of a- or b-klotho. Overexpression of
FLAG-tagged a- or b-klotho does not induce phosphorylation of FRS2a,
ERK1/2, or PLCg in the absence of FGF treatment. GAPDH serves as loading
control.
(B) The four different FGFR isoforms (c splice variants of FGFR1–3) were
overexpressed as V5-tagged fusion proteins in HEK293 cells for 2 days, serum
starved overnight, and treated with FGF23 for 30 min followed by anti-V5
immunoprecipitation from total protein extracts. Endogenous PLCg co-pre-
Cell Metab(Urakawa et al., 2006), the pro-hypertrophic effects of FGF23 on
cardiac myocytes were blocked by pharmacologic inhibition of
phospholipase Cg (PLCg) and calcineurin (Faul et al., 2011). In
contrast, the pro-hypertrophic effects of the prototypical para-
crine FGF family member, FGF2, were blocked by inhibitors
of the Ras/MAPK cascade (Faul et al., 2011). These findings
suggest that different FGF ligands can activate distinct down-
stream signaling pathways in cardiac myocytes and that in the
absence of a-klotho, FGF23 activates the PLCg/calcineurin/nu-
clear factor of activated T cell (NFAT) signaling axis, which is a
potent inducer of pathological LVH (Molkentin et al., 1998). How-
ever, the identity of the specific FGFR that mediates the cardiac
effects of FGF23 is unknown.
The mammalian genome encodes four FGFR isoforms,
FGFR1–4, that are receptor tyrosine kinases (Ornitz and Itoh,
2001). Following ligand-induced auto-phosphorylation of FGFR,
FGF receptor substrate (FRS) 2a undergoes tyrosine phosphory-
lation by FGFR and stimulates Ras/MAPKandPI3K/Akt signaling
(Eswarakumar et al., 2005). In contrast to FRS2a, which is consti-
tutively bound to FGFR independent of the receptor’s activation
state, PLCg can also be recruited to bind directly to one specific
phosphorylated tyrosine residue (pY751 in mouse FGFR4) within
a consensus sequence (YLDL) in the FGFR cytoplasmic tail
(Mohammadi et al., 1991; Vainikka et al., 1994). Subsequent
phosphorylation of PLCg by FGFR activates PLCg (Burgess
et al., 1990), which induces generation of diacylglycerol and
inositol 1,4,5-triphosphate, and increases cytoplasmic Ca2+,
which activates calcineurin and its substrate, NFAT (Eswaraku-
mar et al., 2005). Here, we report our investigation into the
specific FGFR isoform that mediates PLCg signaling and the
pro-hypertrophic effects of FGF23 in cardiac myocytes.
RESULTS
FGF23 Activates FGFR4 and PLCg Signaling in the
Absence of a-Klotho
To study FGF-FGFR-dependent signaling, we used HEK293
cells that express all FGFR isoforms but lack a-klotho (data not
shown), similar to cardiac myocytes (Faul et al., 2011). As a
read-out of calcineurin/NFAT versus Ras/MAPK activation, we
analyzed phosphorylation of PLCg and FRS2a. In response to
30 min of treatment, FGF23 increased phosphorylated PLCg
levels without changing overall PLCg expression, but did not
induce phosphorylation of FRS2a (Figure 1A). In contrast,
FGF2 had no effect on phospho-PLCg levels but increased
phosphorylation of FRS2a and ERK1/2. Thus, in HEK293 cells,
FGF23 and FGF2 activate distinct FGFR adaptor proteins, which
could explain their differential downstream signaling in cardiac
myocytes (Faul et al., 2011).
To test if the presence of a-klotho determines whether FGF23
activates FGFR-mediated downstream signaling by PLCg/calci-
neurin/NFAT or FRS2a/Ras/MAPK, we introduced ectopic a-klo-
tho into HEK293 cells. Subsequent FGF23 treatment increasedcipitates only with FGFR4. In the absence of FGF23 treatment or if the FGFR4-
Y751F mutant form is overexpressed, PLCg cannot be detected in the eluate.
Immunoprecipitations with control antibody (Ctrl-IgG) do not result in purifi-
cation of V5-FGFR4 or PLCg.
See also Figure S1.
olism 22, 1020–1032, December 1, 2015 ª2015 Elsevier Inc. 1021
phosphorylation of FRS2a and ERK1/2, but did not activate
PLCg (Figure 1A), similar to the response of non-transfected
HEK293 cells to FGF2. In contrast, when we overexpressed
ectopic b-klotho that does not bind FGF23 (Ogawa et al.,
2007), FGF23 induced phosphorylation of PLCg (Figure 1A). As
expected, given its lack of reliance on klotho (Goetz et al.,
2012), FGF2-mediated FRS2a/Ras/MAPK signaling was unaf-
fected by the presence or absence of a-klotho or b-klotho. These
data indicate that in the absence of a-klotho, FGF23-induced
FGFR activation stimulates PLCg signaling, whereas overex-
pression of a-klotho causes a signaling switch to the Ras/
MAPK cascade, similar to cells that endogenously express
a-klotho (Urakawa et al., 2006).
To determine which FGFR isoforms are activated by FGF23 in
the absence of a-klotho, we analyzed FGFR binding to PLCg in
response to FGF23 treatment. HEK293 cells were transfected
with V5-tagged FGFR1, FGFR2, FGFR3, or FGFR4 and incu-
bated with FGF23 or PBS as negative control. After 30 min, we
immunoprecipitated the FGFR isoforms from lysates with anti-
V5 and tested for co-precipitation of PLCg by immunoblot anal-
ysis of eluates. Among the FGFR isoforms, only FGFR4 bound
PLCg in response to FGF23 treatment (Figure 1B). We also over-
expressed a V5-tagged murine FGFR4 cDNA carrying a tyrosine
to phenylalanine substitution at residue 751 (FGFR4-Y751F) that
cannot be phosphorylated and therefore cannot activate PLCg
upon ligand stimulation (Vainikka et al., 1994). In contrast to
wild-type FGFR4, FGFR4-Y751F did not co-precipitate PLCg
upon FGF23 treatment (Figure 1B). Although FGFR1, FGFR3,
and FGFR4 can act as FGF23 receptors in a-klotho expressing
cells (Kurosu et al., 2006), our results indicate that in the absence
of a-klotho, FGF23 can stimulate FGFR4-dependent signaling
by specifically activating PLCg via phosphorylation of FGFR4
at Y751.
FGF23 Activates FGFR4 and PLCg Signaling in Cultured
Cardiac Myocytes
To test whether FGFR4 could function as a FGF23 receptor in
cardiac myocytes, we first analyzed FGFR4 protein expres-
sion in the murine heart with constitutive FGFR4 knockout
(FGFR4/) mice used as negative control (Weinstein et al.,
1998). Immunoprecipitation and western blot analyses of pro-
tein extracts from total hearts and isolated neonatal mouse ven-
tricular myocytes (NMVM) from wild-type mice revealed a signal
with the expected size of FGFR4 (approximately 110 kDa) (Par-
tanen et al., 1991) that was absent in extracts from FGFR4/
mice (Figure 2A). Immunocytochemical analysis confirmed that
FGFR4 is expressed in wild-type, but not FGFR4/, NMVM
(Figure 2B). Flow cytometry analysis of the adult mouse heart
indicated that FGFR4 is expressed by cardiac myocytes and ab-
sent from non-myocytes (Figure 2C). Immunohistochemical
analysis of fresh human heart samples confirmed that FGFR4
protein is also expressed in human cardiac myocytes (Figures
2D and 2E).
To determine if FGF23 can activate FGFR4 in cardiac myo-
cytes, we analyzed binding of PLCg to FGFR4 in isolated
neonatal rat ventricular myocytes (NRVM) that were treated for
30 min with FGF23 or FGF2 as negative control. We immunopre-
cipitated endogenous PLCg from total protein extracts and
analyzed eluates by immunoblotting with antibodies against1022 Cell Metabolism 22, 1020–1032, December 1, 2015 ª2015 ElseFGFR4. Compared to eluates derived from control cells that
were incubated with PBS or FGF2, levels of co-purified FGFR4
were elevated in FGF23-treated NRVM, while total FGFR4 and
PLCg expression levels were unchanged (Figure 3A). In contrast,
when cells were co-treated with an isoform-specific antibody
that blocks FGFR4 exclusively among the FGFR isoforms
and their splice variants (anti-FGFR4; Figures S3A and S3B),
levels of PLCg-bound FGFR4 were not elevated in comparison
to control cells.
To determine if FGF23 could activate calcineurin/NFAT
signaling further downstream, we studied FGF23 effects on the
transcriptional activity of NFAT in NRVM. We conducted chem-
iluminescence reporter assays in NRVM that were transduced
with a cDNA construct encoding for firefly luciferase under
the control of three NFAT binding elements. After 2 hr of treat-
ment, FGF23 caused a significant elevation in luciferase activity
that was blocked by the calcineurin inhibitor, cyclosporine A
(Figure 3B). In contrast, FGF2 did not increase luciferase
activity. This result is consistent with our previous finding that
cyclosporine A could block FGF23-induced, but not FGF2-
induced, hypertrophy of NRVM (Faul et al., 2011). To study if
FGF23-induced NFAT activation is mediated by FGFR4, we
treated luciferase reporter NRVM with FGF23 and anti-FGFR4
or AZD4547, a small-molecule inhibitor of FGFR with greater
affinity for FGFR1–3 versus FGFR4. Anti-FGFR4, but not
AZD4547, blocked FGF23-induced elevation in luciferase activ-
ity (Figure 3B).
Next, we treated NRVM with FGF23 or FGF2 for 30 min and
determined activation of the Ras/MAPK signaling pathway by
western blot analysis of total protein extracts. Consistent with
our previous findings (Faul et al., 2011), FGF2, but not FGF23,
increased levels of phosphorylated FRS2a and ERK1/2 (Fig-
ure 3C), and anti-FGFR4 did not block FGF2-induced phosphor-
ylation of FRS2a and ERK1/2 (Figure 3C).
Overall, our findings in cultured cardiac myocytes parallel our
results in HEK293 cells and indicate that in the absence of a-klo-
tho, FGF23 activates FGFR4, resulting in recruitment of PLCg to
the receptor and activation of calcineurin/NFAT signaling. In
contrast, FGF2 activates Ras/MAPK signaling in NRVM indepen-
dently of FGFR4.
FGFR4 Mediates FGF23-Induced Hypertrophy of
Cardiac Myocytes In Vitro
To determine if FGFR4 mediates the pro-hypertrophic effects
of FGF23, NRVM were co-treated with FGF23 or FGF2 and
a series of receptor antagonists for 48 hr. The anti-FGFR4 block-
ing antibody reduced FGF23-induced, but not FGF2-induced,
hypertrophy (Figures 4A and 4B). The pan-FGFR blocker,
PD173074, inhibited the effects of both FGF2 and FGF23,
whereas the FGFR1–3 inhibitor, AZD4547, prevented FGF2-
induced, but not FGF23-induced, hypertrophy (Figure 4B).
Consistent with our immunocytochemistry findings, both
FGF23 and FGF2 significantly increased expression of the
markers of cardiac hypertrophy, atrial, and brain natriuretic pep-
tide (ANP, BNP), whereas pan-FGFR inhibition blocked these ef-
fects (Figure 4C). In contrast, anti-FGFR4 specifically inhibited
FGF23-mediated increases in ANP and BNP expression, indi-
cating that these pro-hypertrophic effects of FGF23 on NRVM
require FGFR4 activation.vier Inc.
Figure 2. FGFR4 Is Expressed in Cardiac Myocytes
(A) Immunoprecipitation of FGFR4 from total heart tissue (H) and isolated ventricular myocytes of newborn wild-type and FGFR4 knockout (FGFR4/) mice
(NMVM) followed by immunoblotting for FGFR4 reveals the expected 110-kDa signal of FGFR4 in wild-type, but not FGFR4/, mice. The 50-kDa signal is the IgG
heavy chain of anti-FGFR4.
(B) Immunocytochemical analysis shows a striated localization pattern of FGFR4 (red) in wild-type NMVM that is absent in FGFR4/ cells. In wild-type NMVM,
FGFR4 is present only in cardiacmyocytes, but not other co-purified cells, as evident by FGFR4 labeling of a-actinin expressing cells (green). DAPI (blue) identifies
nuclei (original magnification, 340; scale bar, 50 mm).
(C) Representative dot blots of three independent flow cytometric analyses of single cell suspensions from adult wild-typemouse hearts. Labelingwithout primary
antibodies is used as negative control (). Numbers refer to percentages of quadrant analysis. FGFR4 is present in cardiac troponin-T (TNNT2)-positive my-
ocytes, whereas TNNT2-negative non-myocytes show no FGFR4 labeling.
(D) Immunoperoxidase labeling of fresh human cardiac tissue with anti-FGFR4 shows a positive signal that is absent if only secondary antibody is used (Ctrl). As
positive control, human liver tissue shows high levels of FGFR4 expression.
(E) Immunohistochemical analysis of human cardiac tissue with anti-FGFR4 (green) shows labeling of the myocardium, as visualized by differential interference
contrast (DIC), and of cardiac myocytes, as identified by co-labeling with anti-a-actinin (red). Fluorochrome-conjugated secondary antibody only was used as
negative control (Ctrl). DAPI (blue) shows nuclei. As positive control, anti-FGFR4 shows strong immunolabeling of hepatocytes in human liver tissue.
See also Figure S2.In support of this finding, 48 hr of treatment with FGF23
induced an increase in cross-sectional area of wild-type
NMVM, but not NMVM from FGFR4/ mice (Figures 4D and
4E). In contrast, FGF2 and the pro-hypertrophic angiotensin
(Ang) II induced hypertrophic growth of NMVM independently
of FGFR4. In wild-type NMVM, FGF23, FGF2, and AngII all
increased expression of b-myosin heavy chain (b-MHC) protein,
which is a fetal MHC isoform that is upregulated in cardiac hy-
pertrophy (Izumo et al., 1987), but only FGF2 and AngII induced
this effect in FGFR4/ NMVM (Figures 4F and 4G). These data
indicate that the pro-hypertrophic effects of FGF23 in cultured
cardiac myocytes require FGFR4.
FGFR4 Loss of Function Protects Mice with Elevated
FGF23 from LVH
To determine if FGFR4 mediates FGF23-induced LVH in vivo,
we elevated endogenous serum FGF23 levels in wild-type
and constitutive FGFR4/ mice by administering 12 weeksCell Metabof a high phosphate (2%) diet that is known to induce LVH
(Hu et al., 2015). Serum phosphate and FGF23 levels
increased significantly in both wild-type and FGFR4/ mice
in the absence of changes in kidney function (Figures 5A–
5C). In response to high phosphate diet, wild-type mice devel-
oped LVH, marked by increases in left ventricular (LV) wall
thickness, cross-sectional area of individual cardiac myo-
cytes, and myocardial fibrosis (Figures 5D–5G). In contrast,
FGFR4/ mice did not develop LVH or fibrosis despite their
similar degree of FGF23 elevation (Figures 5D–5G). High
phosphate diet increased cardiac levels of phosphorylated
PLCg and expression of regulator of calcineurin 1 (RCAN1),
an established NFAT target gene (Yang et al., 2000), in
wild-type mice but not in FGFR4/ mice (Figures S5A and
S5B). We conclude that FGFR4 is required for activation of
cardiac PLCg/calcineurin/NFAT signaling and development
of LVH and myocardial fibrosis in mice with high serum
FGF23 levels.olism 22, 1020–1032, December 1, 2015 ª2015 Elsevier Inc. 1023
Figure 3. FGF23 Activates FGFR4 in Cultured Cardiac Myocytes
(A) NRVM were co-treated with FGF23 or FGF2 and a FGFR4 blocking anti-
body (anti-FGFR4) for 30min followed by anti-PLCg immunoprecipitation from
total protein extracts. The amount of co-precipitated FGFR4 is increased in
cells that were treated with FGF23 compared to FGF2-treated or untreated
cells. In the presence of anti-FGFR4, levels of FGFR4 in anti-PLCg eluates are
reduced. Immunoprecipitation with control antibody (Ctrl-IgG) does not result
in purification of PLCg or FGFR4.
(B) FGF23 treatment of NFAT-luciferase reporter NRVM for 2 hr significantly
increases luciferase activity compared to vehicle- and FGF2-treated cells. The
effect is blocked in cells that were co-treated with cyclosporine A (CsA) or anti-
FGFR4, but not with the FGFR1–3 inhibitor, AZD4547. Values represent
fold change in relative light units ± SEM compared with vehicle treated cells;
*p < 0.0001.
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Nephrectomy Rat Model of CKD
We tested the therapeutic potential of interfering with cardiac
FGF23-FGFR4 signaling in the 5/6 nephrectomy rat model of
CKD that develops increased FGF23 levels, severe hyperten-
sion, and LVH within 14 days after nephrectomy (Faul et al.,
2011). We administered the specific anti-FGFR4 blocking
antibody (25 mg/kg body weight via intraperitoneal injection)
beginning 1 hr after nephrectomy and then every 3 days through
day 12. At day 14 after nephrectomy, renal function was signifi-
cantly impaired and blood pressure and serum FGF23 levels
significantly elevated in the animals that underwent 5/6 versus
sham nephrectomy, but there were no significant differences
between 5/6 nephrectomized animals that received anti-
FGFR4 antibodies or PBS (Table S1). Compared to PBS-treated
5/6 nephrectomized rats, treatment with anti-FGFR4 antibody
significantly attenuated LVH and myocardial fibrosis, as demon-
strated by significant decreases in ratio of heart weight to tibia
length, LV mass, LV wall thickness, cross-sectional area of
individual cardiac myocytes, and collagen fiber content (Figures
6A–6F). Consistent with our histological findings, expression an-
alyses for markers of cardiac hypertrophy and fibrosis confirmed
the protective effects of anti-FGFR4 (Figures 6G and 6H). Echo-
cardiographic analyses revealed no significant systolic changes
in ejection fraction among the three groups (Figure 6I). How-
ever, compared with vehicle-treated 5/6 nephrectomzied rats,
anti-FGFR4 treatment significantly improved diastolic function
(Figure 6J). Anti-FGFR4 treatment attenuated the 5/6 nephrec-
tomy-induced increase in cardiac expression levels of the
NFAT target genes, RCAN1 and transient receptor potential
channel 6 (TRPC6; Figures S5C and S5D). These data indicate
that blocking FGFR4 inhibits cardiac calcineurin/NFAT signaling
and attenuates the development of LVH and cardiac fibrosis in a
well-established animal model of CKD without significantly
altering kidney function, blood pressure, or FGF23 levels.
Constitutive FGFR4 Activation Causes LVH in Mice
Gain-of-function mutations in human FGFR4 are associated with
malignancy (Bange et al., 2002). In the FGFR4Arg388 allele, re-
placing a neutral glycine with a charged arginine residue in the
transmembrane domain increases protein stability and prolongs
phosphorylation of FGFR4 (Wang et al., 2008). Knockinmicewith
the murine homolog, FGFR4Arg385, show advanced tumor
development and accelerated metastasis when exposed to car-
cinogens (Seitzer et al., 2010). We hypothesized that expression
of FGFR4Arg385 predisposes to cardiac hypertrophy. As re-
ported previously (Seitzer et al., 2010), FGFR4 expression is un-
changed in the heart of homozygous knockin mice (FGFR4Arg/
Arg385) compared to wild-type (FGFR4Gly/Gly385). However,
unlike wild-type littermates, 6-month-old FGFR4Arg/Arg385
mice demonstrated LVH, as indicated by significant increases
in heart weight, LV wall thickness, cross-sectional area of
individual cardiac myocytes, and cardiac expression of BNP(C) NRVMwere treatedwith FGF23 or FGF2 for 30min followed by immunoblot
analysis of total protein extracts. Only FGF2 causes an increase in levels of
phospho-FRS2a and phospho-ERK. This effect is not reduced in the presence
of anti-FGFR4. GAPDH serves as loading control.
See also Figure S3.
vier Inc.
Figure 4. FGF23-Mediated Hypertrophic Growth of Isolated Cardiac Myocytes Requires FGFR4
(A) Immunofluorescence confocal images of isolated NRVM that were co-treated with FGF2 or FGF23 and anti-FGFR4 for 48 hr. Myocytes are labeled with anti-
a-actinin (red), and DAPI (blue) identifies nuclei (original magnification,363; scale bar, 50 mm). NRVM treatedwith FGF23 or FGF2 appear larger than PBS-treated
control cells. Anti-FGFR4 blocks the effect of FGF23, but not FGF2.
(B) Comparedwith PBS-treated control cells, 48 hr of treatment with FGF23 or FGF2 significantly increases cross-sectional area of isolated NRVM (mean ± SEM).
Co-treatment with the pan-FGFR inhibitor, PD173074, prevents any increase in area regardless of the FGF. Inhibition of FGFR1–3 by AZD4547 prevents FGF2-
induced, but not FGF23-induced, hypertrophy. An FGFR4-specific blocking antibody (anti-FGFR4) prevents FGF23-induced, but not FGF2-induced, hypertrophy
(150 cells per condition; n = 3 independent isolations of NRVM; *p < 0.0001 compared with vehicle).
(C) Quantitative PCR analysis of NRVM 48 hr after co-treatment with FGF2 or FGF23 with PD173074 or anti-FGFR4. ANP and BNP expression are significantly
elevated in FGF2- and FGF23-treated cells. PD173074 blocks the effects of both FGF2 and FGF23, but anti-FGFR4 blocks only the effects of FGF23 (n = 3
independent isolations of NRVM; *p < 0.05 compared with vehicle).
(D) Immunofluorescence confocal images of NMVM isolated from wild-type or FGFR4/ mice that were treated with FGF2, FGF23, or AngII. Myocytes are
labeled with anti-a-actinin (red), and DAPI (blue) identifies nuclei (original magnification, 363; scale bar, 50 mm). Wild-type NMVM treated with FGF23, FGF2, or
AngII appear larger than PBS-treated control cells. FGFR4/ NMVM increase in size in response to FGF2 and AngII, but are protected from the effect of FGF23.
(E) FGF23, FGF2, and AngII induce significant increases in cross-sectional area of wild-type NMVM, but only FGF2 and AngII increase the size of NMVM isolated
from FGFR4/ mice (150 cells per condition; n = 3 independent isolations of NMVM; *p < 0.01 compared with vehicle).
(F) NMVM were treated with FGF23, FGF2, or AngII for 48 hr followed by immunoblot analysis with anti-b-MHC and anti-GAPDH, and signal quantification by
densitometry. FGF23 induces increased b-MHC expression in wild-type, but not FGFR4/, NMVM, whereas FGF2 and AngII increase b-MHC in NMVM of both
genotypes (values represent fold change ± SEM compared with vehicle-treated cells; n = 4 independent isolations of NMVM; *p < 0.05).
(G) Representative immunoblots for the quantification presented in (F). GAPDH shows equal protein loading. See also Figure S4.(Figures 7A–7D and 7F). FGFR4Arg/Arg385 mice did not show
increased content of myocardial collagen fiber (Figures 7B and
7E), but expression levels of some fibrotic markers were signifi-Cell Metabcantly elevated (Figure 7G). Echocardiography revealed that
compared to control mice, FGFR4Arg/Arg385 mice had signifi-
cantly increased systolic ejection fraction and relative LV wallolism 22, 1020–1032, December 1, 2015 ª2015 Elsevier Inc. 1025
Figure 5. Diet-Induced Elevation of Serum FGF23 Does Not Result in LVH in FGFR4–/– Mice
(A–C) Compared to normal chow (Ctrl), high phosphate diet (Pi) significantly increases serumphosphate (A) and FGF23 (B) levels in wild-type (WT) and constitutive
FGFR4 knockout (FGFR4/) mice, but does not affect blood urea nitrogen (BUN) levels (C).
(D) Representative gross pathology of mid-chamber (MC) sections of the heart (H&E stain; original magnification,35; scale bar, 2mm) and wheat germ agglutinin
(WGA)-stained sections (original magnification, 363; scale bar, 50 mm) demonstrate LVH, and picrosirius red stainings (original magnification, 310; scale bar,
100 mm) showmyocardial fibrosis in wild-typemice on high phosphate diet. FGFR4/mice on high phosphate or wild-type and FGFR4/mice on normal diet do
not develop LVH or fibrosis.
(E–G) Wild-type mice on high phosphate diet develop significant increases in left ventricular (LV) wall thickness (E), cross-sectional area of individual cardiac
myocytes (F), and myocardial deposition of collagen fibers (G), which do not occur in FGFR4/mice on high phosphate diet or wild-type and FGFR4/mice on
normal diet.
All values are mean ± SEM (n = 4–11mice per group; n = 100 cells per group for WGA analysis; *p < 0.001 compared with mice form the same genotype on normal
chow). See also Figure S5.thickness, and a trend toward diastolic dysfunction (p = 0.06;
Figures 7H–7J). Interestingly, serum FGF23 levels were signifi-
cantly increased in FGFR4Arg/Arg385 compared to FGFR4Gly/
Gly385 mice (Figure 7K), but there was no relationship between
FGF23 levels and LV wall thickness (r2 = 0.01; p = 0.67). Thus,
expression of a constitutively active FGFR4 variant is sufficient
to induce LVH in mice, independently of FGF23 levels.
FGFR4Arg385 activated NFAT in the mouse heart, marked
by elevated RCAN1 expression in cardiac extracts from
FGFR4Arg/Arg385 versus FGFR4Gly/Gly385 mice (Figures
S5E and S5F). We overexpressed V5-tagged FGFR4Arg385 in
HEK293 cells for 2 days followed by treatment with FGF23 or
solvent for 30 min. In the absence of FGF23, cells expressing
FGFR4Arg385 showed increased phosphorylation of PLCg
and expression of the RCAN isoforms 1–4 (Figure S7). Treat-
ment of FGFR4Arg385 cells with FGF23 further increased
phospho-PLCg levels (Figure S7), whereas neither the presence
of FGFR4Arg385 nor treatment with FGF23 induced ERK1/2
phosphorylation. This is consistent with findings in mitotic cells,
in which FGFR4Arg385 induces proliferation, but does not acti-
vate Ras/MAPK signaling (Ezzat et al., 2013; Seitzer et al.,
2010). As we have shown for a-klotho-independent, FGF23-
mediated activation of wild-type FGFR4, we conclude that the
glycine-to-arginine substitution at codon 385 of murine FGFR4
constitutively activates PLCg/calcineurin/NFAT signaling, which
might underlie the LVH phenotype observed in FGFR4Arg/
Arg385 knockin mice.1026 Cell Metabolism 22, 1020–1032, December 1, 2015 ª2015 ElseDISCUSSION
We report several findings that advance our understanding
of FGF23, FGFR, and klotho biology. We demonstrate that
FGFR4 is the cardiac receptor for FGF23 and that FGF23 can
activate FGFR4 in cardiac myocytes in the absence of its co-re-
ceptor in the kidney, a-klotho. Unlike most reported FGF-FGFR
interactions that stimulate phosphorylation of FRS2a or FRS2b
and activate Ras/MAPK signaling (Eswarakumar et al., 2005),
we provide direct evidence that FGFR4 binding by FGF23 acti-
vates the PLCg/calcineurin/NFAT signaling axis, which is known
to be a potent inducer of LVH in response to other pathological
stimuli (Wilkins et al., 2004).
In addition to FGF23-induced hypertrophic growth of cardiac
myocytes, FGFR4-induced PLCg activation might function as
a general pathway that mediates other non-mitogenic effects
of specific FGF ligands. Indeed, previous studies showed that
autophosphorylation of the PLCg docking site of FGFR1 and
consequent PLCg activation is not required for the FGF-induced
mitogenic response, but is essential for other FGF-regulated
functions (Mohammadi et al., 1992; Peters et al., 1992; Sorokin
et al., 1994). Since Ras/MAPK signaling is the major pathway
of FGF-mediatedmitogenic effects, but FGFR4 seems to primar-
ily activate PLCg (Shaoul et al., 1995; Vainikka et al., 1994), it is
likely that FGFR4 activation does not induce cell proliferation,
as supported by the much weaker mitogenic response of cells
that express FGFR4 compared to FGFR1 or FGFR2 (Ornitzvier Inc.
Figure 6. Pharmacological Inhibition of FGFR4 Attenuates LVH in a Rat Model of CKD
(A and B) Comparedwith sham nephrectomy, 5/6 nephrectomy (Nx) in rats results in increased ratio of heart weight to tibia length (A) and increased left ventricular
mass (LVM) by echocardiography (B) at day 14 post-surgery. Each of these effects is attenuated by administering an FGFR4-specific blocking antibody (anti-
FGFR4) (*p < 0.05 compared with Sham).
(C) Representative gross pathology sections (H&E stain; original magnification, 32.5; scale bar, 2 mm), wheat germ agglutinin (WGA)-stained sections (original
magnification,363; scale bar, 50 mm), and picrosirius red stainings (original magnification,310; scale bar, 100 mm) from the left ventricular mid-chamber (MC) at
day 14 after 5/6 nephrectomy.
(D–F) Compared with vehicle, anti-FGFR4 attenuates the effects of 5/6 nephrectomy to increase left ventricular (LV) wall thickness (by gross pathology, (D), cross-
sectional area of individual cardiacmyocytes (E), andmyocardial fibrosis (F). All values aremean ± SEM (n = 6–14 rats per group; *p < 0.001 comparedwith Sham;
#p < 0.01 compared with 5/6 nephrectomy treated with vehicle).
(G and H) Quantitative PCR analysis of cardiac tissue shows that expression levels of hypertrophic markers (ANP, BNP, and b-MHC) (G) and of some fibrotic
markers (TIMP metallopeptidase inhibitor 1, Timp1; collagen type 1 alpha 1, Col1a1; collagen type 3 alpha 1, Col3a1) (H) are significantly elevated in 5/6 ne-
phrectomy rats that were treated with vehicle, but not in anti-FGFR4 treated rats (n = 6 rats per group; *p < 0.05 compared with Sham).
(I and J) Echocardiography shows no significant differences in ejection fraction among the three groups (I), but anti-FGFR4 significantly improves diastolic
function (E/E’) in 5/6 nephrectomy rats compared to vehicle-treatment (J) (n = 6–8 rats per group; *p < 0.05 compared with vehicle-injected 5/6 nephrectomy).
See also Figures S5 and S6.et al., 1996). These findings might also explain why previous
in vitro studies that assayed MAPK activity or cell proliferation
as measures of FGFR activation failed to demonstrate activation
of any FGFR by FGF23 in the absence of a-klotho (Kurosu et al.,
2006; Urakawa et al., 2006; Zhang et al., 2006).
Compared to the other FGFR isoforms, FGFR4 also has
weaker kinase activity that results in less pronounced auto-
phosphorylation and weaker phosphorylation of PLCg (Raffioni
et al., 1999; Shaoul et al., 1995; Vainikka et al., 1992). This couldCell Metabexplain why studies that assayed tyrosine phosphorylation
of FGFR4 or PLCg following FGF stimulation failed to show
FGFR4 activation. Our results suggest that studying the inter-
action of FGFR4 and PLCg by immunoprecipitation is a more
sensitive approach to detect FGFR4 activation than assessing
tyrosine phosphorylation of either protein.
Previous analyses of cardiac FGFR4 expression yielded con-
tradictory results (Fon Tacer et al., 2010; Seitzer et al., 2010).
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tissue from constitutive FGFR4/ mice as negative control, we
provide strong evidence that the FGFR4 protein is present in mu-
rine and human hearts and most likely expressed only in myo-
cytes versus other cardiac cell types. We further show that
FGFR4 activation per se appears to be sufficient to induce car-
diac remodeling, as suggested by spontaneous development
of LVH independently of FGF23 levels in mice expressing consti-
tutively active FGFR4. Based on these findings, we speculate
that FGFR4 activation triggers a pro-hypertrophic signaling
pathway in the heart that may also be operative in other forms
of heart disease that feature aberrant ventricular remodeling.
Another aspect of this report is our finding that a-klotho acts
not only as a co-receptor that enhances FGF23 binding to
FGFRs, as previously thought (Urakawa et al., 2006), but also
as a molecular switch that directly influences differential recruit-
ment of distinct signaling cascades downstream of FGFR.
Instead of inducing global FGF23 resistance, our results suggest
that CKD and other pathologic states of a-klotho deficiency may
promote a switch in FGF23-induced signaling that drives
different cellular responses to FGF23 in cells that express
FGFR4 but not a-klotho. Some of these effects may be ultimately
maladaptive, for example, LVH. Furthermore, by demonstrating
that specific FGFR4 blocking antibodies attenuate LVH in 5/6
nephrectomized rats, our results suggest that FGFR4 activation
is a critical molecular mechanism underlying LVH in states of
a-klotho deficiency and FGF23 excess (Faul et al., 2011; Hu
et al., 2015).
Although FGF23 and FGF2 can both induce hypertrophic
growth of cardiac myocytes, FGF23 does so primarily by stimu-
lating PLCg/calcineurin/NFAT signaling, whereas FGF2 acti-
vates the Ras/MAPK signaling axis (Faul et al., 2011). Our study
indicates that the different FGFs activate distinct downstream
signaling pathways by binding and activating different FGFR
isoforms. We show that FGF23, but not FGF2, can activate
FGFR4 on cardiac myocytes and that FGFR4 blockade or dele-
tion inhibits hypertrophic effects of FGF23, but not of FGF2.
Since cardiac myocytes express multiple FGFR isoforms, and
FGFR1 serves as the primary FGF2 receptor in other cell types
(Ornitz et al., 1996), we postulate that FGFR1 mediates the
cardiac hypertrophic effects of FGF2. Further experimental ana-
lyses using FGFR1 loss-of-function approaches are needed to
test this hypothesis. Interestingly, it has been recently shown
that the cardiac myocyte-specific overexpression of a constitu-
tively active mutant form of FGFR1 in mice causes cardiac
hypertrophy (Cilvik et al., 2013). Combinedwith our gain-of-func-
tion model for FGFR4, we conclude that myocardial FGFR1 or
FGFR4 activation is sufficient to induce LVH.
We also observed that rodents with elevated serum FGF23
levels but global loss of FGFR4 function are protected from
developing cardiac fibrosis. Whether this finding is based on
direct effects of FGF23 on cardiac fibroblasts or altered commu-
nication between cardiac myocytes and fibroblasts in the course
of cardiac injury requires further study, for example, by gener-
ating and investigating mouse models that carry cardiac myo-
cyte-specific or cardiac fibroblast-specific deletions of FGFR4.
In addition to its cell biology findings, this report also has
important implications for drug development and future clinical
management of patients with CKD. Previously, we reported
that delivery of a pan-FGFR inhibitor could prevent development1028 Cell Metabolism 22, 1020–1032, December 1, 2015 ª2015 Elseof LVH and reverse established LVH in rats with CKD (Di Marco
et al., 2014; Faul et al., 2011). These proof-of-concept findings
suggested a therapeutic paradigm to attenuate cardiovascular
disease in patients with CKD, but toxicity of pan-FGFR inhibitors
precludes this approach in humans (Yanochko et al., 2013).
Similarly, monoclonal antibodies that neutralize FGF23 are
likely to be of limited utility in CKD because complete abroga-
tion of FGF23 effects causes severe hyperphosphatemia that
results in diffuse vascular calcification and increased mortality
(Shalhoub et al., 2012). Our results suggest that it may
be possible to selectively target FGFR4 to block the toxic
effects of FGF23 in the heart without interfering with the essen-
tial effects of FGF23 to regulate phosphate homeostasis.
Furthermore, whether FGFR4 activation mediates other adverse
effects of elevated FGF23 levels in patients with CKD that could
also be attenuated by selective FGFR4 blockade requires further
study.
EXPERIMENTAL PROCEDURES
Study Approval
All animal protocols and experimental procedures were approved by the Insti-
tutional Animal Care and Use Committees at the University of Miami Miller
School of Medicine (high-phosphate diet in wild-type and FGFR4/ mice),
the Max Planck Institute for Biochemistry in Martinsried (FGFR4Arg385
knockin mouse), and the University of Mu¨nster (5/6 nephrectomy in rats).
Autopsies and postmortem analyses of human tissue were approved by the
medical ethics committee of the Hannover Medical School.
5/6 Nephrectomy Rat Model of CKD
Kidney disease was induced in Sprague Dawley rats using the 5/6 nephrec-
tomy method (Di Marco et al., 2014). Rats were randomized to the following
three groups of six animals each: sham nephrectomy, 5/6 nephrectomy plus
intraperitoneal injections of vehicle (PBS), or 5/6 nephrectomy plus intraperito-
neal injections of anti-FGFR4 blocking antibody (human monoclonal, U3-11;
U3Pharma) at 25 mg/kg/day every 3 days beginning 1 hr after surgery. Four-
teen days after surgery, echocardiography and blood pressure measurements
were performed, animals were sacrificed, and the hearts were isolated and
prepared for histological and serological analyses.
High Phosphate Diet in FGFR4–/– Mice
Five 6-month-old constitutive FGFR4/ mice on the C57BL/6 background
(Weinstein et al., 1998) and 11wild-type littermates were switched from normal
chow to a 2.0% phosphate diet (Teklad 08020, Harlan) for 12 weeks. Four
9-month-old wild-type and four FGFR4/mice that weremaintained on a reg-
ular diet served as negative controls. Animals were sacrificed and the hearts
were isolated, perfused ex vivo (6 ml of 10% formalin with 4 ml of 20 mM
KCl), stored overnight in 10% formalin for fixation, and then serially sectioned
(7-mm slices) and stained with H&E.
FGFR4Arg385 Knockin Mice
FGFR4Arg385 knockinmice on the C57BL/6 backgroundwere generated (Seit-
zer et al., 2010). Homozygous FGFR4Arg/Arg385 male and female mice were
analyzed, and wild-type littermates (FGFR4Gly/Gly385) served as negative con-
trols. Nine to twelve animals per group were sacrificed at 6 months of age, and
the hearts were isolated and prepared using the same protocol as described
above.
Morphology, Fluorescence Microscopy, and Morphometry of Mouse
and Rat Hearts
Short-axis heart sections were stained with H&E (VWR) and used to quantify
myocardial thickness by measuring the distance from the inner to the outer
myocardial edges at the mid-chamber zone. Mean left ventricular free wall
thickness was calculated from seven measurements of wall thickness taken
at 0, 30, 60, 90, 120, 150, and 180 degrees along the hemi-circle of the shortvier Inc.
Figure 7. Knockin Mice with an FGFR4 Gain-of-Function Mutation Spontaneously Develop LVH
(A) Six-month old homozygous knockin mice carrying the Arg385 substitution in FGFR4 (FGFR4Arg/Arg385) manifest significant increases in the ratio of heart
weight to tibia length compared with wild-type littermates (FGFR4Gly/Gly385) (mean ± SEM; n = 9–12 mice per group; *p < 0.01).
(B) Representative gross pathology of mid-chamber (MC) sections of the heart (H&E stain; original magnification,35; scale bar, 2 mm) and wheat germ agglutinin
(WGA)-stained sections (original magnification,363; scale bar, 50 mm) demonstrate LVH in FGFR4Arg/Arg385mice but lack of myocardial fibrosis by picrosirius
red staining (original magnification, 3100; scale bar, 100 mm).
(C–E) Compared with wild-type, FGFR4Arg/Arg385 mice develop significant increases in left ventricular (LV) wall thickness (mean ± SEM; n = 9–12 mice per
group; *p < 0.01) (C) and cross-sectional area of individual cardiac myocytes (mean ± SEM; n = 100 cells per group; *p < 0.0001) (D), but no difference in collagen
deposition (mean ± SEM; n = 9–12 mice per group) (E).
(F) Quantitative PCR analysis of total hearts frommice reveals significantly elevated BNP expression in 6-month-old FGFR4Arg/Arg385mice comparedwith wild-
type (n = 4–6 mice per group; *p < 0.01).
(G) Quantitative PCR analysis of cardiac tissue shows that expression levels of some fibrotic markers (TIMP metallopeptidase inhibitor 1, Timp1; collagen
type 1 alpha 2, Col1a2; collagen type 5 alpha 1, Col5a1) are significantly elevated in FGFR4Arg/Arg385mice compared to wild-type mice (n = 6 mice per group;
*p < 0.01).
(legend continued on next page)
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axis of the free wall. Images were taken on a Nikon SMZ 1500 microscope us-
ing 0.753 magnification.
We measured the cross-sectional area of individual cardiac myocytes
in paraffin-embedded short-axis sections of mouse and rat hearts. Briefly,
7-mm-thick sections were deparaffinized according to our established proto-
cols (Faul et al., 2011). To visualize cellular borders, fixed tissue was incubated
with wheat germ agglutinin (WGA) conjugated to Alexa Fluor555 (Invitrogen) at
1 mg/ml in PBS containing 10mM sodium azide. Immunofluorescence images
were taken on a Leica TCS-SP5 confocal microscope with a 633 oil objective.
Leica AF6000 fluorescence software was used to quantify cross-sectional
area of 25 cells per field at 4 fields along the mid-chamber free wall based
on WGA-positive staining.
Short-axis cardiac sections frommice and rats were stained with picrosirius
red (Sigma-Aldrich) and used to quantify myocardial fibrosis. Sections were
deparaffinized, counterstained with hematoxylin (VWR), and incubated in
picrosirius red solution for 60 min. After washing in acidified water, sections
were dehydrated in ascending ethanol series and mounted in non-aqueous
mounting media. For quantification of myocardial fibrosis, 10 images were
taken around the complete left ventricle using an Olympus BX41 microscope
with 103magnification. Collagen content was determined by quantification of
picrosirius-red-positive area per field of view using ImageJ software (NIH).
We analyzed RCAN1 expression in paraffin-embedded short-axis sections
of mouse and rat hearts by immunoperoxidase staining. 7-mm-thick sections
were deparaffinized and rehydrated, and antigen retrieval was performed
using a citrate acid-based antigen unmasking solution (Vector Laboratories
H-3300). After blocking endogenous peroxidase activity with 1% H2O2 for
20 min, non-specific sites were blocked with goat serum blocking solution
(Sigma-Aldrich) for 1 hr. Sections were incubated in primary antibody
(anti-RCAN1 at 1:50 [Harrison et al., 2004]) overnight and immunostained em-
ploying the avidin-biotin enzyme complex (ABC; Thermo Scientific) method.
Reaction products were visualized by 3,30-diaminobenzidine (DAB; Vector
Laboratories). After dehydration in ascending alcohol, series sections were
mounted and images were taken using an Olympus BX41 microscope with
103 magnification.
Echocardiography of Mouse and Rat Hearts
High-resolution echocardiography (15 MHz) in rats was performed at 14 days
after surgery to assess LV mass, wall and chamber dimensions, and sys-
tolic and diastolic function using an HDI 5000 Ultrasound system (Philips).
M-mode, 2D, and 3D recordings were obtained under general anesthesia
delivered through a nose mask while heart rate and body temperature were
maintained. Echocardiography in mice was conducted as described for rats.
Relative wall thickness was estimated as [interventricular septum diastolic
(IVSd) + LV posterior wall diastolic (LVPWd)]/LV diameter diastolic (LVDd).
Blood pressure was measured in conscious rats using a computerized rat-
tail cuff technique (CODA, Kent Scientific).
Immunocytochemistry and Morphometry of Isolated Cardiac
Myocytes
Cultured cardiac myocytes were fixed in 2% paraformaldehyde (PFA) (in
5 mg/ml sucrose) for 5 min and permeabilized in 1% Triton X-100 (in PBS)
for 10 min. We analyzed hypertrophic growth of isolated NRVM and NMVM
on laminin-coated glass coverslips after 48 hr of treatment with growth factors.
For FGFR4 expression and localization analyses, untreated NMVM from
wild-type and FGFR4/ mice were immunolabeled. The mouse monoclonal
antibody against sarcomeric a-actinin (EA-53; Sigma-Aldrich) was used
at 1:1,000, and rabbit polyclonal anti-FGFR4 (C-16; Santa Cruz) at 1:50.
Cy3-conjugated goat-anti mouse and Alexa488-conjugated goat-anti rabbit
(Jackson ImmunoResearch) were used as secondary antibodies at 1:300. To
visualize nuclei, fixed cells were incubated with 4’,6-diamidino-2-phenylindole
(DAPI; 400 ng/ml in PBS) for 10 min. Immunofluorescence images were taken
on a Leica TCS-SP5 confocal microscope with a 633 oil objective.(H–J) Echocardiography shows that compared towild-typemice, relative wall thic
FGFR4Arg/Arg385 mice (n = 5–9 mice per group; *p < 0.05).
(K) FGFR4Arg/Arg385mice demonstrate increased serum FGF23 levels compare
See also Figures S5 and S7.
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staining using Leica AF6000 fluorescence software. To assess the signaling
pathways involved in FGF23- and FGF2-mediated hypertrophy, we analyzed
the morphometry of plated cells that were pre-treated with specific inhibitors
for 60 min prior to the addition of the FGFs at 25 ng/ml (NRVMs) or at
100 ng/ml (NMVMs). The following inhibitors and concentrations were used:
pan-FGFR, PD173074 (Sigma Aldrich) at 10 nM (Mohammadi et al., 1998);
FGFR1–3, AZD4547 (ChemieTek) at 5 nM (Gavine et al., 2012); and FGFR4
blocking antibody (human monoclonal, U3-11; U3Pharma) at 10 mg/ml.
Statistical Analysis of In Vitro and Animal Data
Data are presented as mean ± SEM. ANOVA and t tests were used for statis-
tical inference with two-tailed p values < 0.05 considered significant. No sta-
tistical method was used, but extensive laboratory experience from previous
publications was used to predetermine sample size. No formal randomization
was used in any experiment; for in vivo experiments, animals were unbiasedly
assigned into different treatment groups. Group allocation was not performed
in a blinded manner. Whenever possible, experimenters were blinded to the
groups (e.g., in immunofluorescence and immunohistochemistry experiments
by hiding group designation and genotype of animals until after quantification
and analysis). No animals or samples were excluded from data analysis.
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